Product Images Lorbrena

This is a comparison between LORBRENA (N= 149) and Crizotinib (N=147) in terms of median survival. LORBRENA achieved a median that was not reached, while Crizotinib achieved a median of 9.3 months. The hazard ratio for LORBRENA was 0.28 with a 95% confidence interval of (0.19, 0.41) and p-value < 0.0001. The graph shows the survival time (months) for each group.*

This is a description of a company or a product that is distributed by Pfizer Labs, a division of Pfizer Inc. located in New York, NY 10017.*

This text is simply stating that the company Pfizer Inc has a division called Pfizer Labs that distributes their products.*

This is a prescription medication called Lorbrena (lorlatinib) that comes in the form of tablets. It is recommended to store the medication at room temperature between 20°C to 25°C (68°F to 77°F) or permissible between 10°C to 30°C (50°F to 86°F), and dispense in child-resistant containers. The dosage and specific use instructions can be found in the accompanying prescribing information. Each tablet contains 25mg of lorlatinib, and it is distributed by U.S. Pharmaceuticals Pfizer Inc. in New York. The provided details include a professional sample not for sale, NDC number 63539-927-0, LOT number, and GTIN number.*